Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca Halts Three Clinical Trial Programs, Reports Six Quarters of Top-line Growth

At the very end of its 2015 half-year financial report, on page 49, AstraZeneca PLC (AZN) noted the termination of three projects between April 1 and June 30. They were a program for selumetinib for uveal melanoma, tenapanor for ESRD-pi/CKD with T2DM and Nexium for refractory reflux esophagitis. The selumetinib and tenapanor programs were halted […]

Read More »

Watch Out Gilead, Investors Feel Vertex May Be Biogen’s Good Fit

July 31, 2015By Alex Keown, Breaking News Staff CAMBRIDGE, Mass. – A Bloomberg survey of 30 investors indicates Biogen (BIIB) needs to enter the M&A fray sooner than expected in order to boost revenue, the business site reported this morning. Asthika Goonewardene, a health-care analyst for Bloomberg Intelligence, said the Boston-based drugmaker should acquire […]

Read More »

Health insurer Cigna says second-quarter medical costs stay low; profit beats

Health insurer Cigna Corp, which agreed last week to be bought by Anthem Inc for $47 billion, said on Thursday that medical services use was low in the second quarter, helping to keep costs in check and beat Wall Street profit estimates. Cigna’s report of a continued low utilization trend backs up a growing industry […]

Read More »

Teva’s MS drug Copaxone has strong second-quarter sales

Teva Pharmaceutical Industries (TEVA.N), which this week revealed plans to buy Allergan’s (AGN.N) generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world’s biggest generic drug maker, said that global […]

Read More »

Sanofi’s diabetes sales slow, Genzyme’s jump

* Q2 Business net income up 4.2 percent, above expectations * Analyst says Toujeo sales “underwhelming” * CEO Brandicourt to unveil strategic plan on Nov.6, open to M&A * Shares down 0.45 percent (Adds details, shares, comments) By Matthias Blamont and Noëlle Mennella PARIS, July 30 (Reuters) – Sanofi reported lower second quarter sales for […]

Read More »

AstraZeneca Boosted by Licensing Deals

By Denise Roland The Wall Street Journal Biography @deniseroland Updated July 30, 2015 7:51 a.m. ET AstraZeneca PLC on Thursday reported an increase in second-quarter revenue, thanks to proceeds from licensing deals, though profits continued to fall as the company plowed heavy investment into new drugs it hopes will replace its old blockbusters. The […]

Read More »

PAREXEL International Stays Mum as 200 Ex-GlaxoSmithKline Workers are Reportedly Being Laid Off Today

July 30, 2015By Mark Terry, Breaking News Staff Reportedly, almost 200 former GlaxoSmithKline (GSK) employees who were transferred earlier this year to Parexel (PRXL) are being laid off today. The company has declined to comment directly on the matter. In December 2014, Boston, Mass.-based Parexel (PRXL) announced it was hiring 450 former GSK employees. […]

Read More »

Four Boston Biotechs That Could Make M&A Moves This Year

July 29, 2015By Alex Keown, Breaking News Staff BOSTON – It’s been the year of deal making with more than $220 billion spent on mergers and acquisitions in the biotech industry, and it’s not over yet. Although no M&A activity has been announced, at least as of this writing, but given the atmosphere that […]

Read More »

Vertex Revenue Rises 20%

By Tess Stynes The Wall Street Journal Biography @TessStynes July 29, 2015 4:42 p.m. ET   Vertex Pharmaceuticals Inc. said its second-quarter revenue rose 20% on strong sales of Kalydeco that led the biotechnology company to raise its 2015 sales guidance for the cystic-fibrosis drug. Shares rose 1.5% to $127.50 in recent after-hours trading […]

Read More »

Gilead Sales Soar on Hepatitis Drugs

Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected sales of the newer Harvoni. For the year, the company again raised its guidance for net product sales, this time by $1 billion, and now […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom